[
  {
    "ts": "2025-11-20T12:00:09+00:00",
    "headline": "Is Amgen Inc. (NASDAQ:AMGN) A High Quality Stock To Own?",
    "summary": "While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...",
    "url": "https://finance.yahoo.com/news/amgen-inc-nasdaq-amgn-high-120009012.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "60903d67-8a06-3248-b0c0-3a96b3385396",
      "content": {
        "id": "60903d67-8a06-3248-b0c0-3a96b3385396",
        "contentType": "STORY",
        "title": "Is Amgen Inc. (NASDAQ:AMGN) A High Quality Stock To Own?",
        "description": "",
        "summary": "While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...",
        "pubDate": "2025-11-20T12:00:09Z",
        "displayTime": "2025-11-20T12:00:09Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ACuIXYrNeojUXbAJFhnPIg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/B7CQJIEa.2c0sQ0XIU66pg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/8ab44b8ef28c7f69299492d5b9c5a46c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/amgen-inc-nasdaq-amgn-high-120009012.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/amgen-inc-nasdaq-amgn-high-120009012.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-20T13:05:00+00:00",
    "headline": "Accord BioPharma, Inc. Announces FDA Approval of Denosumab Biosimilars OSVYRTI® (denosumab-desu) and JUBEREQ® (denosumab-desu)",
    "summary": "Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, announced today the U.S. Food and Drug Administration (FDA) approval of OSVYRTI® (denosumab-desu), a biosimilar to Prolia® (denosumab), and JUBEREQ® (denosumab-desu), a biosimilar to Xgeva® (denosumab).1-2 The dual approvals mark Accord BioPharma's fourth and fifth biosimilars, demonstrating the company's continued growth in the U.S. market.",
    "url": "https://finance.yahoo.com/news/accord-biopharma-inc-announces-fda-130500162.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "eeb47334-ef55-3de2-b2c7-68ac5158dad1",
      "content": {
        "id": "eeb47334-ef55-3de2-b2c7-68ac5158dad1",
        "contentType": "STORY",
        "title": "Accord BioPharma, Inc. Announces FDA Approval of Denosumab Biosimilars OSVYRTI® (denosumab-desu) and JUBEREQ® (denosumab-desu)",
        "description": "",
        "summary": "Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, announced today the U.S. Food and Drug Administration (FDA) approval of OSVYRTI® (denosumab-desu), a biosimilar to Prolia® (denosumab), and JUBEREQ® (denosumab-desu), a biosimilar to Xgeva® (denosumab).1-2 The dual approvals mark Accord BioPharma's fourth and fifth biosimilars, demonstrating the company's continued growth in the U.S. market.",
        "pubDate": "2025-11-20T13:05:00Z",
        "displayTime": "2025-11-20T13:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/e6bd7ab07828d0ffe7ac9f8294e5ac5d",
          "originalWidth": 400,
          "originalHeight": 271,
          "caption": "Accord BioPharma Logo (PRNewsfoto/Accord BioPharma)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dxi4WKXo0gUzffQUoCxKGw--~B/aD0yNzE7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/e6bd7ab07828d0ffe7ac9f8294e5ac5d.cf.webp",
              "width": 400,
              "height": 271,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/azDPImK.0RW2bISHBi98lw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/e6bd7ab07828d0ffe7ac9f8294e5ac5d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/accord-biopharma-inc-announces-fda-130500162.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/accord-biopharma-inc-announces-fda-130500162.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]